24 Roy Street
Seattle, WA 98109
Complete this contact form for media, investor relations and partnership/business development inquiries
Please leave this field empty.
* required fields
A Feasibility Study of the EMulate Therapeutics Voyager System in Patients with Recurrent Glioblastoma Multiforme (rGBM). This study is currently recruiting qualified patients.
Abstract presented by Xavier Figueroa, PhD, at Society for Neuro-Oncology 2016 Annual Conference, Scottsdale, AZ on November 19, 2016.
The latest information on publications highlighting EMulate Therapeutics research and advancements.
April 9, 2019
A feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma in Australia
An early feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma: first cohort in US
March 19, 2019
Nativis Announces Name Change To EMulate Therapeutics, Inc.
EMulate Therapeutics Voyager® ulRFE® System for rGBM is an investigational medical device. Limited by United States law to investigational use only.
© EMulate Therapeutics 2019. All rights reserved.